Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial.
about
Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.Early ileocolonoscopy with biopsy for the evaluation of persistent post-transplantation diarrheaDoes reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry.Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients.Impact of the early reduction of cyclosporine on renal function in heart transplant patients: a French randomised controlled trial.Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation.A Protocol for the Pharmacokinetics of Enteric Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN): an open-label, randomised controlled trialTacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF GenomicsPharmacogenetic influences on mycophenolate therapy.Impact of Mycophenolate Mofetil Dose Reduction on Allograft Outcomes in Kidney Transplant Recipients on Tacrolimus-Based Regimens: A Systematic Review.The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation.Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?Optimization of pediatric rheumatology therapeutics.Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.Is it time to give up with calcineurin inhibitors in kidney transplantation?Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysisHow accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients.Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis.Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation.Therapeutic drug monitoring of mycophenolate in adult solid organ transplant patients: an update.Therapeutic drug monitoring of enteric-coated mycophenolate sodium by limited sampling strategies is associated with a high rate of failure.Maintenance immunosuppressants in the management of antibody-mediated renal allograft rejection: which regimen is best?Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience.What is the intrapatient variability of mycophenolic acid trough levels?Interleukin receptor antagonist induction in kidney transplantation: Is it worth the price?Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials NetworkTacrolimus exposure in the real world: an analysis from the Mycophenolic acid Observational REnal transplant study.Impact of acute rejection on kidney allograft outcomes in recipients on rapid steroid withdrawal.Enteric-coated mycophenolate sodium.Limited sampling strategies for predicting area under the concentration-time curve of mycophenolic acid in islet transplant recipients.Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring.Acute humoral rejection in pediatric renal transplant recipients receiving steroid minimization immunosuppression.Exposure to mycophenolic acid better predicts immunosuppressive efficacy than exposure to calcineurin inhibitors in renal transplant patients.Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†).Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium?Pharmacokinetics and target attainment of mycophenolate in pediatric renal transplant patients.
P2860
Q33764989-4A0BDD33-3594-4AA9-A6A4-19C72BC0E813Q34063731-0CA287E0-2540-48FB-A62A-B2269CCA3565Q34365272-FD6203D6-16B6-4BF5-AE81-FA1BD16CDD38Q35619332-CD9A4FB5-D0B3-4DD0-8B88-E1BE1486FA08Q36498564-18418A12-C101-4D21-8A78-D548F2CEB802Q37013588-4C446079-6F32-4FC1-808B-F65DAA5AABE2Q37086991-AA0B64A7-4950-40A3-B2AC-2BDE94E79522Q37209745-B06329EB-BA82-4D45-BE52-51DB735C06BBQ37710509-50257B1D-4EBA-43AB-85F9-78055ABC352AQ37838123-6B800D33-25C0-48DB-B13D-8B1F51CEB788Q37857285-14661DDE-5F08-4C15-90FA-FB7A29A907DCQ37939057-8BDC33B0-A56E-42A9-B5BD-929D182AECF4Q37956717-B2610E4E-D59E-43FE-AE94-479A7B323411Q37991520-ECCE9AF6-91E0-4E88-A72F-CADB4CED1DF4Q38087925-AD74E2AC-0610-4F58-B736-4A57BF2016EBQ38156847-EFCAC99B-40D8-4CAD-B69E-683D9D78655FQ38164111-5EC6D0CE-F15A-4A43-81F5-EBDD3C12B3C6Q38170321-D817609B-645E-41F2-A545-8DFB33A0739EQ38208983-E1411755-B4A8-4EFE-8F12-BC9C7592E07AQ38417581-FFA370EE-61FB-4E27-BA0A-6F362F35FFA6Q38668601-5A9490CF-7338-4E24-9C0C-A985BBD0364EQ38779769-954E8557-7FC6-49A5-AFD3-BAB60D5F7855Q38786418-1D9D0E9D-9EBD-4000-8E19-C679746FCA03Q38791599-4F43A4C2-F6C8-4C60-BFB9-9B86D91EECACQ39016704-B937C702-F8A0-4090-9225-3FD4C77EBA51Q39045577-5B2FD079-4F6F-4E3E-9965-F19DA6416CD1Q40015538-0427595D-A139-4603-8A10-1194F72629D0Q40707992-3B4BBF4D-A5EE-431B-A3DB-D6BBB0CD75F4Q41828996-5D5A385E-2135-4888-8806-4ED5891AC8DEQ42149848-18E885FA-882B-4941-9029-8A14473D60E2Q42222999-D1EE59A0-DB25-4273-AD6D-82CC1A5F55C7Q42740954-30165077-83D8-4EEC-B5F5-3792095574A6Q42925114-73EE16DC-2DA8-4AB1-B14E-E0469331741FQ43227279-55A37060-3DF1-48FD-B894-5FF81AFF37F7Q43776939-400134D7-E9ED-4074-860B-54C4EF36C68BQ44534960-2D7BCA3C-B061-49E6-BF11-1CD1A39891BBQ44738359-22C09845-820C-43C6-BAC1-3838FD1E79BAQ46005342-D330C015-8782-4298-8B15-8C8A9DFEC49CQ51745633-B49B7341-2B05-479F-B00B-6C3E54D09C93Q53163992-EEB18D77-70D5-479D-89CC-A9151505B286
P2860
Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Fixed- or controlled-dose myco ...... nhibitors: the Opticept trial.
@en
Fixed- or controlled-dose myco ...... nhibitors: the Opticept trial.
@nl
type
label
Fixed- or controlled-dose myco ...... nhibitors: the Opticept trial.
@en
Fixed- or controlled-dose myco ...... nhibitors: the Opticept trial.
@nl
prefLabel
Fixed- or controlled-dose myco ...... nhibitors: the Opticept trial.
@en
Fixed- or controlled-dose myco ...... nhibitors: the Opticept trial.
@nl
P2093
P1476
Fixed- or controlled-dose myco ...... nhibitors: the Opticept trial.
@en
P2093
H-U Meier-Kriesche
R S Gaston
S Mulgaonkar
P304
P356
10.1111/J.1600-6143.2009.02668.X
P407
P577
2009-05-20T00:00:00Z